Mach7’s US imaging win puts speed back on the scan

Mach7 Technologies has added a useful new US customer, signing American Radiologist Network Inc, better known as AMRADNET, to a five-year annual subscription licence for its eUnity Viewer. The initial contract value is A$1.7 million, based on a minimum of 675,000 imaging studies a year, with volumes projected to exceed one million studies during the five-year term.

For a company with a market value sitting in the small-cap healthcare tech basket, this is not a company-making deal on its own. But investors are unlikely to view it solely through the dollar figure. The more interesting part is what the contract says about Mach7’s execution, the scalability of eUnity and the company’s attempt to shorten what has historically been a long and lumpy enterprise software sales cycle.

Why AMRADNET matters

AMRADNET is a US-based teleradiology provider whose SaaS-based Radiology Informatics Portal connects US board-certified radiologists with healthcare facilities for remote imaging interpretation and reporting. Its client base has expanded from long-term acute care and skilled nursing institutions into hospitals, outpatient centres, urgent care centres and diagnostic clinics. It is also pushing into cardiology, neurology and broader telemedicine services.

That matters because teleradiology is a volume game. The more studies flowing through a platform, the more important speed, interoperability and reliability become. Mach7’s eUnity Viewer is designed for high-volume diagnostic image access, which makes the AMRADNET win a useful reference point in a US market where remote care and distributed reporting models continue to gain ground.

The deployment rabbit pulled from the hat

The standout metric is not only the A$1.7 million contract value. It is the expected time to first productive use: within 45 days. Mach7 says this is a significant reduction from its typical 12-month deployment timeline, attributing the improvement to the removal of silos and a restructuring of its sales and services teams.

For investors, that is the sort of operational detail worth lingering over. Enterprise imaging software sales can be painfully slow, with procurement, integration, compliance and workflow redesign all conspiring to make revenue conversion feel like watching paint dry in a dark room. A 45-day expected go-live timetable, if repeated elsewhere, could improve revenue visibility, customer onboarding and cash conversion.

Chief executive and managing director Teri Thomas framed the deal as both a customer win and an execution marker, saying AMRADNET was building “a scalable and rapidly growing teleradiology platform” and that the speed from evaluation to first productive use highlighted both AMRADNET’s operational focus and the strength of eUnity in “fast-moving, high-volume imaging environments”.

Recurring revenue, but mind the fine print

The contract is structured as an annual subscription licence, which is positive for investors who prefer repeatable revenue over one-off software sales. However, the released details describe an initial contract value rather than spelling out potential upside mechanics if AMRADNET’s imaging volumes exceed the minimum threshold. So while the projected lift beyond one million studies a year is encouraging, investors should avoid assuming a linear revenue kicker unless Mach7 provides more detail.

Mach7’s broader platform combines a Vendor Neutral Archive, the eUnity Enterprise Diagnostic Viewer and its Flamingo suite of modules, supporting workflow, interoperability and data management across complex healthcare environments. The company says its software is built for interoperability and scalability, while also being aligned with cloud ecosystems including Amazon Web Services.

Market reaction says investors noticed

The key question now is repeatability. One fast deployment is interesting. Several would be evidence. Mach7 has told investors it is changing the way it sells and implements software. AMRADNET gives the company a live test case for that claim in a commercially relevant part of the US healthcare system.

For now, the deal is a tidy contract with a potentially larger message: Mach7 is trying to turn enterprise imaging from a slow-moving hospital IT grind into a more scalable, subscription-led growth story. In small-cap health tech, where promises often travel faster than implementations, shaving deployment time from 12 months to 45 days is the sort of thing that will get investors peering more closely at the scan.